December 2011 Vol XXXV Issue 12

Previous MonthNext Month


ENDOSCOPY: OPENING NEW EYES, SERIES #6

Biliary Stone Extraction Techniques: Old and New

Farid Jalali, Andrew K. Roorda, Uma Sundaram

The purpose of this publication is to provide an overview of the features, techniques, indications, clinical efficacy, safety, and potential complications of various methods of bile duct stone removal.



Diseases of the Pancreas, SERIES #3

Antioxidant Supplementation in Chronic Pancreatitis: Current Evidence An Overview

Natalia Hernandez, Nicholas Perez, Sandeep Patel, Laura Rosenkranz

This review focuses on the accumulated evidence and recent progress in understanding the role of the nutritional components in the management of chronic pancreatitis.



Fellows corner

Deceptive Gastrointestinal Morbidity

Alexander Schlachterman, Asyia S. Ahmad

This case of a prepyloric gastric-ruptured ulcer highlights the life-threatening visceral perforation that is possible after cocaine use.



A Case Report

An Unusual Finding of Colonic Schwannoma

Mark Friedman, Veena Nannegari, Dave Jones, Seth Richter

In this case we discuss gastrointestinal schwannomas - uncommon, benign nerve sheath tumors that arise from the schwann cells of the neural plexus of the digestive wall. It is important to correctly diagnose a gastrointestinal schwannoma, as it needs to be distinguished from tumors which may be malignant or have malignant potential.



Departments Section


From the Literature

Evaluation of EUS-FNA Cytopathology to Improve Sensitivity

EUS-guided FNA (EUS-FNA) with cytologic analysis yields a diagnostic accuracy that varies from 60 to 90%, with a specificity near 100% in pancreatic carcinoma. To determine the sensitivity and specificity of detection of chromosomal abnormalities by fluorescence in situ hybridization (FISH), analysis was studied with selective use of FISH in patients with inconclusive onsite cytopathology results to note possible improvement in the sensitivity of EUS for malignancy.



Progression of Advanced Chronic Hepatitis C

In order to evaluate the incidence of liver disease progression among subjects with histologically advanced, but compensated chronic hepatitis C, the "Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis" trial was carried out. This was a randomized study of 3. 5 years of maintenance PEG Interferon treatment on liver disease progression among patients who had not cleared virus ontherapy with PEG Interferon and Ribavirin.



Entecavir for HBV with a Partial Virological Response

To investigate the long-term efficacy and safety of Entecavir (ETV) in nucleoside or nucleotide analoguenaive chronic hepatitis B (CHB) patients, particularly in those with detectable HBV DNA after 48 weeks in whom treatment adaptation is suggested by current guidelines, a multicenter cohort study was carried out.



Obesity and Clinical Decompensation in Cirrhosis

Obesity is associated with an aggressive course in chronic viral hepatitis. In order to evaluate its impact in the development of clinical decompensation (CD) in patients with established cirrhosis, its role in relationship to other recognized predictors, and the development of CD with compensated cirrhosis was evaluated.



Medical Bulletin Board

OraSure Technologies Receives CLIA Waiver for OraQuick® HCV Rapid Test

BETHLEHEM, PA. OraSure Technologies, Inc. (NASDAQ:OSUR) announced that the U.S. Food and Drug Administration ("FDA") has granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for its OraQuick® HCV Rapid Antibody Test for use with fingerstick whole blood and venous whole blood specimens.



STERIS CORPORATION INTRODUCES AMSCO® V-PRO® maX LOW TEMPERATURE STERILIZATION SYSTEM

Newest vaporized hydrogen peroxide system offers departments a flexible new cycle and unique capabilities



Transplant Candidates Seek Best Quality Livers, Even if it Means Waiting Longer

U-M researcher finds patients would rather be on waiting list than accept an organ with higher risk of failure. More than 42 percent of patients would choose More than 42 percent of patients would choose to remain on the waiting list rather than accept a "lower quality" liver according to the study’s lead author Michael L. Volk, M.D., M.S., assistant professor in U-M’s Department of Internal Medicine, Division of Gastroenterology.